Mammogen raised up to $30 million in a Series A equity round to support clinical testing of genTRU-breast, its mRNA-based blood assay designed for earlier detection of breast cancer. The company said the test uses PCR to detect 26 mRNA biomarkers from a single blood draw and targets women with heterogeneously or extremely dense breast tissue. The financing announcement ties to recent US federal policy requiring mammography reports to disclose breast density categories, creating a defined population in which supplemental screening is more common and false negatives can be higher. Mammogen said it aims for a price point no higher than $500 to reduce downstream imaging and biopsy burdens estimated at $11 billion annually.